Ketamine-induced sclerosing cholangitis: a case series.

IF 1.2 4区医学 Q4 GASTROENTEROLOGY & HEPATOLOGY

Acta gastro-enterologica Belgica Pub Date : 2025-07-01 DOI:10.51821/88.3.13914

A Vanrusselt, J Nijs, L Van den Bergh, N Schoofs, S Smets, D Strybol, A Rappaport

{"title":"Ketamine-induced sclerosing cholangitis: a case series.","authors":"A Vanrusselt, J Nijs, L Van den Bergh, N Schoofs, S Smets, D Strybol, A Rappaport","doi":"10.51821/88.3.13914","DOIUrl":null,"url":null,"abstract":"Background: Ketamine-induced sclerosing cholangitis is an under-recognized but emerging condition, associated with chronic recreational ketamine use (1,2). While the bladder dysfunction related to ketamine abuse is well-documented, its hepatobiliary complications are less known (3). The disease mechanism remains unclear. It is suspected that ketamine has an effect on N-methyl-D-aspartate receptors in the bile duct smooth muscle, which contributes to chronic inflammation, fibrosis, and strictures. Patients present with abnormal liver function tests, imaging abnormalities, and aberrant liver biopsy. Management requires cessation of ketamine use, symptomatic treatment and close monitoring to prevent progression to cirrhosis (4-8).Cases: This case series presents two cases of ketamine-induced sclerosing cholangitis in female patients, a demographic not typically represented in existing literature.Conclusion: A multidisciplinary approach involving gastroenterologists, urologists, and psychiatrists is necessary (5). Long-term studies are needed to better understand the pathophysiology and to approve treatment and management of this disease.","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":"88 3","pages":"271-276"},"PeriodicalIF":1.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta gastro-enterologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.51821/88.3.13914","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Ketamine-induced sclerosing cholangitis is an under-recognized but emerging condition, associated with chronic recreational ketamine use (1,2). While the bladder dysfunction related to ketamine abuse is well-documented, its hepatobiliary complications are less known (3). The disease mechanism remains unclear. It is suspected that ketamine has an effect on N-methyl-D-aspartate receptors in the bile duct smooth muscle, which contributes to chronic inflammation, fibrosis, and strictures. Patients present with abnormal liver function tests, imaging abnormalities, and aberrant liver biopsy. Management requires cessation of ketamine use, symptomatic treatment and close monitoring to prevent progression to cirrhosis (4-8).

Cases: This case series presents two cases of ketamine-induced sclerosing cholangitis in female patients, a demographic not typically represented in existing literature.

Conclusion: A multidisciplinary approach involving gastroenterologists, urologists, and psychiatrists is necessary (5). Long-term studies are needed to better understand the pathophysiology and to approve treatment and management of this disease.

查看原文本刊更多论文

氯胺酮诱导的硬化性胆管炎：一个病例系列。

背景：氯胺酮诱导的硬化性胆管炎是一种未被充分认识但正在出现的疾病，与慢性娱乐性氯胺酮使用有关（1,2）。虽然氯胺酮滥用引起的膀胱功能障碍有充分的证据，但其肝胆并发症却鲜为人知(3)。这种疾病的发病机制尚不清楚。我们怀疑氯胺酮对胆管平滑肌中的n -甲基- d -天冬氨酸受体有影响，从而导致慢性炎症、纤维化和狭窄。患者表现为肝功能检查异常、影像学异常和肝活检异常。管理需要停止使用氯胺酮，对症治疗和密切监测，以防止进展为肝硬化（4-8）。病例：本病例系列介绍了两例氯胺酮诱导的硬化性胆管炎女性患者，在现有文献中没有典型的人口统计学代表。结论：胃肠病学家、泌尿科医生和精神科医生参与的多学科方法是必要的。需要长期的研究，以更好地了解病理生理学和批准治疗和管理这种疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta gastro-enterologica Belgica Medicine-Gastroenterology

CiteScore

2.30

自引率

20.00%

发文量

期刊介绍： The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.